The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.
3d
The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
The global single-use assemblies market, valued at US$ 2.52 billion in 2023, is forecasted to grow at a robust CAGR of 13.2%, ...
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a leading ...
In a report released on January 13, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a ...
12d
BMO Capital analyst Evan Seigerman has maintained their neutral stance on MRK stock, giving a Hold rating on January 10.Stay Ahead of the ...
Industry Dominated by Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Merck KGaA, BD (Becton, Dickinson and Company), and Eppendorf AG Global Laboratory Consumables Market Global Laboratory ...
Term life insurance is a type of life insurance that runs for a specific amount of time, for example, 10, 20, or 40 years. If you pass away during this time frame, your loved ones will get a cash lump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback